Secondary prophylaxis in an adult patient with severe haemophilia A Factor VIII consumption and effectiveness

被引:2
|
作者
Schlenkrich, S. [1 ]
Schubert, C. [1 ]
机构
[1] HELIOS Clin Ctr Erfurt, Erfurt, Germany
来源
HAMOSTASEOLOGIE | 2013年 / 33卷 / 03期
关键词
Haemophilia; secondary prophylaxis; adult; bleeding rate; factor VIII consumption;
D O I
10.5482/HAMO-12-07-0013
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Primary prophylaxis has been proven as the gold standard for preserving joint function in severe haemophilia. Secondary prophylaxis in children has also been shown to have a more beneficial effect on joint protection as on-demand treatment. The outcome of delayed secondary prophylaxis started in adulthood is rarely studied. The case of a man (age: 47 years) with severe haemophilia A demonstrates the successful switch from on-demand therapy to prophylaxis with subsequent reduction of annual bleeding rate and number of days of work lost. The small increase of factor VIII consumption (16%) and the decrease of bleeding rate are compared with data from two recently published prospective studies. Conclusion: An optimal dosing schedule needs to be discussed and larger and longer prospective studies targeting the benefits of secondary prophylaxis with factor VIII started in adulthood are necessary.
引用
收藏
页码:241 / 244
页数:4
相关论文
共 50 条
  • [31] Successful liver transplantation in a patient with severe haemophilia A and a high-titre factor VIII inhibitor
    Ashrani, AA
    Reding, MT
    Shet, A
    Osip, J
    Humar, A
    Lake, JR
    Key, NS
    HAEMOPHILIA, 2004, 10 (06) : 735 - 737
  • [32] Prevalence of Obesity in Young Patients with Severe Haemophilia and Its Potential Impact on Factor VIII Consumption in Germany
    Olivieri, Martin
    Koenigs, Christoph
    Heller, Christine
    Horneff, Silvia
    Oldenburg, Johannes
    Halimeh, Susan
    Kentouche, Karim
    Knoefler, Ralf
    Fischer, Lars
    Pfrepper, Christian
    Kurnik, Karin
    Bidlingmaier, Christoph
    HAMOSTASEOLOGIE, 2019, 39 (04): : 355 - 359
  • [33] Safety, efficacy and cost-effectiveness of home therapy with recombinant activated factor VII in a patient with severe haemophilia A and an anti-factor VIII inhibitor
    Stewart, AJ
    Hanley, JP
    Ludlam, CA
    BLOOD COAGULATION & FIBRINOLYSIS, 1998, 9 : S93 - S95
  • [34] Two de novo factor VIII gene mutations in the family of an isolated severe haemophilia A patient
    Kapsimali, Z.
    Pavlova, A.
    Pergantou, H.
    Adamtziki, E.
    Oldenburg, J.
    Platokouki, H.
    HAEMOPHILIA, 2012, 18 (01) : E3 - E4
  • [35] Targeting higher factor VIII levels for prophylaxis in haemophilia A: a narrative review
    Malec, Lynn
    Matino, Davide
    HAEMOPHILIA, 2023, 29 (06) : 1419 - 1429
  • [36] Factor VIII Half Life Through Pharmacokinetics Using two Blood Samples in Children With Severe Haemophilia A on Prophylaxis
    Komitopoulou, A.
    Pergantou, H.
    Kapsimali, Z.
    Mazarakis, M.
    Dettoraki, A.
    Platokouki, H.
    HAEMOPHILIA, 2017, 23 : 36 - 36
  • [37] CLINICAL RESULTS OF CONTINUOUS PROPHYLAXIS IN PATIENTS WITH SEVERE HAEMOPHILIA AFTER CHANGE IN FACTOR VIII OF EXTENDED AVERAGE LIFESPAN
    Mingot Castellano, M. E.
    Nunez, R.
    Martin, S.
    Entrena Urena, L.
    Fernandez, C.
    Palomo Bravo, A.
    Dominguez, J. F.
    HAEMATOLOGICA, 2019, 104 : 123 - 123
  • [38] Intracranial haemorrhage in a boy with severe haemophilia A and factor VIII inhibitor
    Laguna P.
    Klukowska A.
    Child's Nervous System, 2006, 22 (4) : 432 - 435
  • [39] Inversions of the factor VIII gene in Slovenian patients with severe haemophilia A
    Strmecki, L
    Benedik-Dolnicar, M
    Vidan-Jeras, B
    Komel, R
    EUROPEAN JOURNAL OF HAEMATOLOGY, 1999, 63 (01) : 64 - 66
  • [40] Forum on: the role of recombinant factor VIII in children with severe haemophilia A
    Franchini, M.
    Coppola, A.
    Molinari, A. C.
    Santoro, C.
    Schinco, P.
    Speciale, V.
    Tagliaferri, A.
    HAEMOPHILIA, 2009, 15 (02) : 578 - 586